Different Effects of Epigenetic Modifiers on the Cytotoxicity Induced by 5-Fluorouracil, Irinotecan or Oxaliplatin in Colon Cancer Cells
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
We investigated the effects of epigenetic modifiers such as DNA methyltransferase (DNMT) or histone deacetylase (HDAC) inhibitors on the cytotoxicity induced by 3 anticancer drugs (5-fluorouracil (5-FU), irinotecan (CPT-11) or its active form SN38, and oxaliplatin (L-OHP)) in human colorectal cancer (CRC) cells. Cytotoxicity in 4 CRC cell lines (HT29, SW480, SW48 and HCT116) was examined by colorimetric assay after drug treatment for 72 h. The effects of drug combinations were analyzed by an isobologram method. SW480 cells showed the lowest sensitivity to cytotoxicity induced by the anticancer drugs among the 4 CRC cell lines. In SW480 cells, DNMT inhibitors, such as decitabine (DAC), azacytidine and zebularine (Zeb), showed synergic effects on the cytotoxicity induced by anticancer drugs except for SN-38 plus Zeb, while HDAC inhibitors, trichostatin A, suberoylanilide hydroxamic acid and valproic acid, showed antagonistic effects. DAC showed the most potent synergic effects among the epigenetic modifiers studied. Thus, we examined whether the synergic effect of DAC is observed in other different CRC cell lines, HT29, SW48 and HCT116 cells. In all 4 CRC cell lines, the cytotoxicity of L-OHP was enhanced in a synergic manner by co-treatment with DAC. However, synergic effects of DAC with 5-FU or CPT-11 (SN-38) were not observed in 4 CRC cell lines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, multiple DNMT inhibitors exhibited additive or synergistic effects when combined with 5-FU, oxaliplatin or irinotecan in CRC cell lines [159,160,161].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [160]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity
Gordon Steel, G., & Peckham, M. J. (1979) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(79)90044-0 · Cited by 908
Epigenetic modifications as therapeutic targets
Kelly, T. K., De Carvalho, D. D., & Jones, P. A. (2010) · Nature Biotechnology · doi:10.1038/nbt.1678 · Cited by 793
Tsai, H.-C., Li, H., Van Neste, L., Cai, Y., Robert, C., Rassool, F. V., Shin, J. J., Harbom, K. M., Beaty, R., Pappou, E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.029 · Cited by 650
Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA.
Kim, M. S., Blake, M., Baek, J. H., Kohlhagen, G., Pommier, Y. G., & Carrier, F. (2003) · PubMed · Cited by 529
Sinicrope, F. A., & Sargent, D. J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1469 · Cited by 309
Histone Deacetylase Inhibitors In The Treatment Of Cancer: Overview And Perspectives
Giannini, G., Cabri, W., Fattorusso, C., & Rodriquez, M. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.80 · Cited by 175
de la Chapelle, A. (2003) · New England Journal of Medicine · doi:10.1056/nejmp038099 · Cited by 160
Lind, G. E., Danielsen, S. A., Ahlquist, T. C., Merok, M. A., Andresen, K., Skotheim, R. I., Hektoen, M., Rognum, T. O., Meling, G. I., Hoff, G. S., et al. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-85 · Cited by 145
Crea, F., Nobili, S., Paolicchi, E., Perrone, G., Napoli, C., Landini, I., Danesi, R., & Mini, E. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.08.001 · Cited by 137
Research works printed but not linked: 2
- Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination stud- ies. Pharmacol. Rev., 58, 621-681 (2006). · DOI · Paper page
- Morita S, Iida S, Kato K, Takagi Y, Uetake H, Sugihara K. The synergistic effect of 5-aza-2′-deoxycytidine and 5-fluorouracil on drug-resistant tumors. Oncology, 71, 437-445 (2006). · DOI · Paper page
Cited by
Epigenetics of colorectal cancer: biomarker and therapeutic potential
Jung, G., Hernández-Illán, E., Moreira, L., Balaguer, F., & Goel, A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0230-y · Cited by 813
DNA methylation aberrancies as a guide for surveillance and treatment of human cancers
Liang, G., & Weisenberger, D. J. (2017) · Epigenetics · doi:10.1080/15592294.2017.1311434 · Cited by 150
Nucleosidic DNA demethylating epigenetic drugs – A comprehensive review from discovery to clinic
Agrawal, K., Das, V., Vyas, P., & Hajdúch, M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.006 · Cited by 135
Epigenetic polypharmacology: A new frontier for epi‐drug discovery
Tomaselli, D., Lucidi, A., Rotili, D., & Mai, A. (2020) · Medicinal Research Reviews · doi:10.1002/med.21600 · Cited by 119
“island methylation is responsible for the induction of drug resistance, and this effect can be reversed through the treatment with hypomethylating agents(47-50) including zebularine(50) and decitabine 2.(50,51) The combination of HDACi with cytostatic agents (such as doxorubicin and paclitaxel) has been widely evaluat…”
BackgroundWeisenberger, D. J., Liang, G., & Lenz, H. (2017) · Oncogene · doi:10.1038/onc.2017.374 · Cited by 103
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
DNA methylation biomarkers in colorectal cancer: Clinical applications for precision medicine
Fatemi, N., Tierling, S., Es, H. A., Varkiani, M., Mojarad, E. N., Aghdaei, H. A., Walter, J., & Totonchi, M. (2022) · International Journal of Cancer · doi:10.1002/ijc.34186 · Cited by 75
Huyghe, N. D., Benidovskaya, E., Stevens, P., & den Eynde, M. V. (2022) · Cancers · doi:10.3390/cancers14092241 · Cited by 67
“Various preclinical studies investigate treatments targeting epigenetic changes since these latter are reversible [33,34].”
BackgroundTanaka, S., Hosokawa, M., Ueda, K., & Iwakawa, S. (2015) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b15-00129 · Cited by 47
Self-citationOkada, K., Hakata, S., Terashima, J., Gamou, T., Habano, W., & Ozawa, S. (2016) · Oncology Reports · doi:10.3892/or.2016.5008 · Cited by 35
“Furthermore, synergistic or additive effects have been reported when combining epigenetic agents with existing anticancer drugs (15-17).”
BackgroundTan, Y., Zhang, S., Zhu, H., Chu, Y., Zhou, H., Liu, D., & Huo, J. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2018.11.48 · Cited by 35
“Meanwhile, Won et al. (40) found that A452 could synergistically enhance the chemotherapeutic effect of irinotecan in CRC cells (HCT116 and HT29 cells).”
BackgroundInfluentialNikodijević, D. D., Jovankić, J. V., Cvetković, D. M., Andjelković, M., Nikezić, A. G., & Milutinović, M. G. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174466 · Cited by 28
Effect of lycopene as an adjuvant therapy with 5-florouracil in human colon cancer
Alhoshani, N. M., AL–Johani, N. S., Alkeraishan, N., Alarifi, S. A., & Alkahtani, S. H. (2022) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2022.103392 · Cited by 28
Hosokawa, M., Mai, S., NAKANO, A., Iwashita, S., 石坂綾乃, Ueda, K., & Iwakawa, S. (2015) · Oncology Letters · doi:10.3892/ol.2015.3253 · Cited by 27
“It was previously reported that DAC exhibited a synergic effect on the cytotoxicity induced by anti-cancer drugs in human CRC cells (20).”
InfluentialSelf-citationPereira, V., Lamoine, S., Cuménal, M., Lolignier, S., Aissouni, Y., Pizzoccaro, A., Prival, L., Balayssac, D., Eschalier, A., Bourinet, E., et al. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02361-6 · Cited by 24
Lee, J., Bae, J., Kwak, D., Kim, H., Kim, J., Hlaing, S. P., Saparbayeva, A., Lee, E. H., Yoon, I., Kim, M., et al. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122443 · Cited by 23
Despotović, J., Dragičević, S., & Nikolić, A. (2021) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-021-00980-3 · Cited by 22
“The used concentrations were 2 × IC50 of previously reported values for SW480 cells [28]: 21.”
MethodSanaei, M., & Kavoosi, F. (2020) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2020.21.7.2131 · Cited by 20
Lamoine, S., Cuménal, M., Barrière, D. A., Pereira, V., Fereyrolles, M., Prival, L., Barbier, J., Boudieu, L., Brasset, É., Bertin, B., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010098 · Cited by 20
“In vitro experiments and animal models have shown anti-tumor activities of HDAC inhibitors [33].”
BackgroundEpigenetic Agents in Combined Anticancer Therapy
Kejík, Z., Jakubek, M., Kaplánek, R., Králová, J., Mikula, I., Pavel Martasek, E., & Král, V. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0203 · Cited by 19
Huang, C. L., Zhou, T. Y., Ma, L., & Zhao, S. (2022) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b22-00439 · Cited by 17
Gao, T., Chunlei, C., & Jingjing, W. (2016) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b16-00285 · Cited by 16
Bukowski, K., Marciniak, B., Kciuk, M., Mojzych, M., & Kontek, R. (2022) · Molecules · doi:10.3390/molecules27123761 · Cited by 13
“2 μM for HCT 116 [39,40]), cisplatin (IC50–9 μM for PC-3 and HCT 116 and 12.”
CRISPR/Cas9-directed epigenetic editing in colorectal cancer
Gupta, M. K., Gouda, G., Moazzam‐Jazi, M., Vadde, R., Nagaraju, G. P., & El‐Rayes, B. F. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189338 · Cited by 12
Liu, Z., Wang, H., & Zhang, Z. (2021) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2021.111508 · Cited by 11
Zou, Z., Chen, H., Yu, J., Huang, Z.-H., Fang, S., & Lin, X. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5812 · Cited by 10
“Colorectal cancer (CRC) is the third most common cancer in humans and has a high mortality rate, it is an important public health problem worldwide (1).”
Hakata, S., Terashima, J., Shimoyama, Y., Okada, K., Fujioka, S., Ito, E., Habano, W., & Ozawa, S. (2018) · Oncology Letters · doi:10.3892/ol.2018.7883 · Cited by 12
“Preliminary studies have been conducted on the combined use of DNMT inhibitors with existing antitumor agents (10-12).”
Hosokawa, M., Tanaka, S., Ueda, K., Iwakawa, S., & Ogawara, K. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.12.115 · Cited by 10
Self-citationLee, J., Kim, J., Kwak, D., Kim, H., Ullah, M., Kim, M. C., Hyun, K., Lee, E. H., Yun, H., Jung, Y., et al. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.158935 · Cited by 8
Krbal, L., Hanušová, V., Soukup, J., John, S., Matoušková, P., & Ryška, A. (2016) · Tumor Biology · doi:10.1007/s13277-016-4839-y · Cited by 8
“However, main chemotherapy is based on 5-FU and leucovorin, and the positive cytotoxic effect of irinotecan and oxaliplatin in vitro was tested several times in various colon cancer cells [44, 45], but sensitivity differed.”
BackgroundBalintova, L., Matúšková, M., & Gábelová, A. (2022) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2022.503445 · Cited by 7
Hosokawa, M., Tanaka, S., Ueda, K., & Iwakawa, S. (2017) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b17-00439 · Cited by 7
Self-citationEpigenetic modulators combination with chemotherapy in breast cancer cells
Arı, F., Napieralski, R., Akgün, O., Magdolen, V., & Ulukaya, E. (2021) · Cell Biochemistry and Function · doi:10.1002/cbf.3626 · Cited by 6
“It was already shown in the literature, that the combination of decitabine or valproic acid with chemotherapeutics exhibit synergistic/ additive effects against cancer cells.(56,57) Also, in clinical phase studies, promising results of decitabine combination with valproic acid have been observed in patients with acute…”
BackgroundNikodijević, D. D., Jovankić, J. V., Radenković, N., Cvetković, D. M., Podolski-Renić, A., & Milutinović, M. G. (2024) · Toxin Reviews · doi:10.1080/15569543.2024.2317294 · Cited by 6
“…and biotransformation-related pathways under the influence of Melittin compared to untreated cells. summary of results we tried to show schematically (Figures 4 and 6). considering the literature reports about the less sensitivity of ht-29 cells compared to other cRc cells (ikehata et al .”
ResultBulkurcuoğlu, B., Gürbüz, M. U., Tyčiaková, S., Pavlov, K. P., Mojzesova, N., Matúšková, M., Tülü, M., & Erçelen, Ş. (2024) · Biotechnology Journal · doi:10.1002/biot.202400362 · Cited by 5
Yaylaci, E., Önen, H. İ., & Sağlam, A. S. Y. (2020) · EXCLI journal · doi:10.17179/excli2020-2042 · Cited by 6
“The en- zyme caspase-3 as a marker of apoptosis confirms that the cell has undergone apoptosis at the protein level (Kamsteeg et al., 2003; Kluger et al., 2007; Alvero et al., 2006; Gamble et al., 2006; Ikehata et al., 2014).”
BackgroundA Multicellular 3D GelMA‐Based Colorectal Cancer Model for Chemotherapeutic Responses
Adiguzel, S., Altuntaş, S., Çelikten, Ş., Gündüz, M. C., & Bacanli, M. G. (2026) · Macromolecular Bioscience · doi:10.1002/mabi.70190 · Cited by 2
“Cells were exposed to increasing concentrations of 5-FU (1, 5, 10, 25, 50 ve 100 µ MM ) for 24 and 72 h [ 22, 23 ].”
Niknam, M., Varedi, M., Zamani, M., Mokarram, P., & Naghibalhossaini, F. (2023) · Pharmaceutical Sciences · doi:10.34172/ps.2023.19 · Cited by 1
“22,23 The hypermethylation of the protocadherin-17 promoter in CRC cells has been shown to increase 5-FU chemoresistance by inhibiting 5-FU-induced apoptosis and autophagy.”
BackgroundMahdi, D. S., Mosawi, R. H. A., & Madlum, K. N. (2024) · Medical Journal of Ahl al-Bayt University · doi:10.66068/mjaabu.v3i1.49 · Cited by 1
Tyutyunyk‐Massey, L., Haqqani, S., Mandava, R., Kentiba, K., Dammalapati, M., Dao, N., Haueis, J. R. S., Gewirtz, D. A., & Landry, J. W. (2018) · Advances in cancer research · doi:10.1016/bs.acr.2018.02.001 · Cited by 1
“In other colorectal cancer cell lines, the DNMTis decitabine, azacitidine, and zebularine were tested for sensitization to several chemotherapies which included oxaliplatin (Ikehata et al., 2014).”
BackgroundThe Challenge of Translating System Biology into Targeted Therapy of Cancer
Conforte, A. J., Magalhães, M., Tilli, T. M., da Silva, F. A. B., & Carels, N. (2018) · Computational biology · doi:10.1007/978-3-319-74974-7_10 · Cited by 1
Wang, X., & Chi, P. (2020) · Europe PMC (PubMed Central) · Cited by 1
Gutiérrez, J. A., Giraldo, S. A., & Vásquez, L. A. R. (2023) · Scientia et technica · doi:10.22517/23447214.24723
Development of New Nanotherapeutic Modalities for The Treatment of Colon Cancer
ÖZER, B. O., & Dıbırdık, İ. (2021) · Trakya University's Institutional Open Access System (Trakya University) · Cited by 1
Metadata
- Authors
- Ikehata, M., Ogawa, M., Yamada, Y., Tanaka, S., Ueda, K., & Iwakawa, S.
- Affiliations
- Kobe Pharmaceutical University (JP)
- Venue
- Biological and Pharmaceutical Bulletin
- Publisher
- Pharmaceutical Society of Japan
- Published
- 2014
- Volume
- 37
- Issue
- 1
- Pages
- 67-73
- ISSN
- 0918-6158 (ISSN-L)
- 1347-5215
- OpenAlex
- W2054808842
- Cited by
- 42
- References
- 28
- Citations by year
- 2025: 3 · 2024: 2 · 2023: 2 · 2022: 7 · 2021: 7 · 2020: 4 · 2019: 2 · 2018: 6 · 2017: 3 · 2016: 4 · 2015: 2
- FWCI
- 0.90
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Biological and Pharmaceutical Bulletin (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- epigenetic regulators, colorectal cancer, 5-fluorouracil, irinotecan, SN-38, oxaliplatin, hypomethylating agents, histone deacetylase inhibitors, decitabine, azacitidine, zebularine, trichostatin A, vorinostat, valproic acid, drug synergy, drug antagonism, cytotoxicity, combination therapy
- MeSH terms
- Irinotecan, Oxaliplatin, Decitabine, Antimetabolites, Antineoplastic, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Azacitidine, Camptothecin, Colonic Neoplasms, DNA, Drug Synergism, Fluorouracil, Humans, Organoplatinum Compounds, DNA Modification Methylases, HT29 Cells, Epigenesis, Genetic, HCT116 Cells, Cell Line, Tumor, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.